Video

Dr. Susan Slovin summarizes state of PARP inhibitor use in prostate cancer

Author(s):

Urology Times staff

Susan F. Slovin, MD, PhD, medical oncologist, associate vice chair, Academic Administration, Department of Medicine, Memorial Sloan Kettering Cancer Center, provides a concise summary of the latest information on the state of PARP inhibitors for the treatment of patients with prostate cancer.

Related Videos
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Channing J. Paller, MD, answers a question during a Zoom video interview
Vanita Gaglani, RPT, answers a question during a video interview
Channing J. Paller, MD, answers a question during a Zoom video interview
Jaspreet S. Sandhu, MD, answers a question during a video interview
Related Content
US FDA logo in white over a blue background. | Credit: US Food and Drug Administration
February 4th 2025

FDA Updates in Urology: January 2025

Patrick Campbell
A recap of the FDA submissions and regulatory decisions in urology from January 2025.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Urologist speaking with a male patient following a diagnosis of cancer. | Credit: Adobe Stock
February 4th 2025

Urologic Cancer Facts and Updates for World Cancer Day 2025

Patrick Campbell
A list of facts and trends to know about the current landscape of urologic cancer management and research in the US.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Acute toxicity after prostate cancer radiotherapy increases odds of late toxicity
February 3rd 2025

Acute toxicity after prostate cancer radiotherapy increases odds of late toxicity

Hannah Clarke
The incidence of late grade 2 or greater GU toxicity at 5 years was 12.5% among those who did experience acute toxicity vs 7.5% among those who did not.
MPS2 test validated for detection of high-grade prostate cancer in non-DRE urine
January 30th 2025

MPS2 test validated for detection of high-grade prostate cancer in non-DRE urine

Hannah Clarke
“MPS2 could potentially improve the health of our patients by avoiding overdiagnosis and overtreatment and allowing us to focus on those who are most likely to have aggressive cancers," says Ganesh S. Palapattu, MD, FACS.
© 2025 MJH Life Sciences

All rights reserved.